Contineum Therapeutics
CTNM
63 hedge funds and large institutions have $107M invested in Contineum Therapeutics in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 5 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
2% more funds holding
Funds holding: 62 → 63 (+1)
6% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 18
2.98% less ownership
Funds ownership: 82.87% → 79.89% (-3%)
54% less capital invested
Capital invested by funds: $231M → $107M (-$124M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$1.19M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.08M |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$787K |
| 4 |
Morgan Stanley
New York
|
+$278K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$184K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Stempoint Capital
New York
|
-$3.89M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.93M |
| 3 |
CC
Casdin Capital
New York
|
-$1.35M |
| 4 |
Squarepoint
New York
|
-$784K |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$639K |
CTNM Hedge Fund Activity: Q1 2025 in Review
63 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Contineum Therapeutics (CTNM) for Q1 2025, worth a combined $107M — down 54% from $231M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CTNM positions and 5 closed out — a net gain of 1 holder — while 19 added to existing stakes and 18 trimmed.
The largest buyer was Franklin Resources, adding an estimated $1.19M. The largest seller was Stempoint Capital, exiting entirely with an estimated $3.89M sold.
- 63 institutional investors held Contineum Therapeutics (CTNM) as of Q1 2025, up from 62 in Q4 2024.
- Funds reported $107M of Contineum Therapeutics stock for Q1 2025, down 54% quarter-over-quarter.
- 6 funds opened new Contineum Therapeutics positions in Q1 2025 and 5 closed out, a net change of +1 holder.
- The largest Contineum Therapeutics buyer in Q1 2025 was Franklin Resources, an estimated $1.19M added.
- The largest Contineum Therapeutics seller in Q1 2025 was Stempoint Capital, an estimated $3.89M sold.
Based on aggregated 13F filings for Q1 2025.